FDA panel to review approval of Alzheimer's drug Leqembi
TL;DR Summary
A panel of independent advisors to the FDA is meeting to decide whether the Alzheimer's drug Leqembi, made by Eisai and Biogen, should receive full approval. The FDA is expected to make a final decision on Leqembi on July 6. Leqembi is technically already available on the U.S. market after receiving fast-track approval in January, but very few seniors can access the expensive treatment because Medicare is restricting coverage to only people who are participating in clinical trials.
- FDA advisors to weigh whether Alzheimer's drug Leqembi should receive full approval CNBC
- FDA's Advisers Will Consider Biogen's Alzheimer's Drug Friday. What to Expect. Barron's
- Analysis | FDA advisers to discuss full approval of Alzheimer's drug The Washington Post
- Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer's Disease | Biogen Biogen
- FDA panel to vote on Alzheimer’s drug The Hill
- View Full Coverage on Google News
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
2 min
vs 3 min read
Condensed
86%
566 → 78 words
Want the full story? Read the original article
Read on CNBC